Ignite Creation Date:
2024-05-06 @ 5:18 PM
Last Modification Date:
2024-10-26 @ 2:26 PM
Study NCT ID:
NCT05263570
Status:
RECRUITING
Last Update Posted:
2022-09-13
First Post:
2022-01-17
Brief Title:
The Efficiency for Stage II-III HRHER2 Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World
Sponsor:
Shengjing Hospital
Organization:
Shengjing Hospital
Study Overview
Official Title:
The Efficiency for Patient With Stage II-III HRHER2 Early Breast Cancer With Standard Neoadjuvant Therapy a Retrospective Multicenter Study in Real World Settings
Status:
RECRUITING
Status Verified Date:
2022-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To observe the efficiency for patient with stage II-III HRHER2 early breast cancer with standard neoadjuvant therapy a retrospective multicenter study in real world settings
Detailed Description:
This study collected patients used standard neoadjuvant therapy TCbHPTHPEC-THPAC-THP among stage II-III HRHER2 early breast cancer and to describe patient clinical characteristics and clinical outcomes of them in real world settings
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None